| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
1alpha, 25-Dihydroxy VD2-D6 targets the vitamin D receptor (VDR), a nuclear receptor that regulates gene expression in response to vitamin D. As a deuterated form of vitamin D, it retains the biological activity of the parent compound. Vitamin D plays critical roles in calcium homeostasis, bone metabolism, immune function, and cell proliferation. The compound is a potent regulator with a wide range of biological activities. Its deuterium labeling does not significantly alter its biological activity.
|
|---|---|
| ln Vitro |
In vitro, 1alpha, 25-Dihydroxy VD2-D6 acts as a synthetic analog of vitamin D with potent regulatory effects on gene expression and cellular function. It binds to the vitamin D receptor and modulates the transcription of target genes involved in calcium metabolism, immune function, and cell proliferation. The deuterium labeling allows for its use as an internal standard in analytical assays. Its biological activity is similar to that of non-deuterated vitamin D analogs.
|
| ln Vivo |
In vivo, 1alpha, 25-Dihydroxy VD2-D6 functions as a deuterated form of vitamin D with potential therapeutic and biological effects. Vitamin D plays critical roles in calcium homeostasis, bone metabolism, immune function, and cell proliferation. The compound's deuterium labeling allows for its use in pharmacokinetic studies to track the metabolism and distribution of vitamin D. Further in vivo studies are needed to fully characterize its pharmacokinetic and pharmacodynamic profile.
|
| Enzyme Assay |
For in vitro receptor binding assays, 1alpha, 25-Dihydroxy VD2-D6 can be evaluated using vitamin D receptor (VDR) binding assays. The compound is incubated with recombinant VDR at various concentrations, and binding is quantified using fluorescence polarization, radiometric, or other detection methods. Its ability to activate VDR-mediated transcription can be assessed using reporter gene assays in cells expressing VDR. EC₅0 values are determined from dose-response curves. Standard assay conditions include appropriate buffer systems.
|
| Cell Assay |
For in vitro cellular experiments, 1alpha, 25-Dihydroxy VD2-D6 is tested in cell lines expressing the vitamin D receptor to evaluate its effects on gene expression and cellular function. Cells are cultured in appropriate media and treated with various concentrations of the compound. VDR target gene expression is measured by qPCR or Western blotting. The compound's effects on cell proliferation, differentiation, and calcium metabolism are assessed using standard assays. Its activity is compared to non-deuterated vitamin D analogs.
|
| Animal Protocol |
For in vivo animal experiments, 1alpha, 25-Dihydroxy VD2-D6 can be administered to rodents via various routes including oral gavage, intravenous injection, or intraperitoneal injection. The compound's effects on calcium homeostasis, bone metabolism, and immune function can be evaluated in appropriate animal models. Typical doses may range from 0.1 to 10 microg/kg. Serum calcium levels, bone density, and immune markers are assessed. The deuterium labeling allows for tracking of the compound in pharmacokinetic studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 1alpha, 25-Dihydroxy VD2-D6 are relevant for its use as a deuterated standard. The deuterium labeling allows for accurate quantification of vitamin D metabolites in biological samples using mass spectrometry. As a vitamin D analog with a molecular weight of 434.68, it is expected to have similar pharmacokinetic properties to non-deuterated vitamin D. Detailed parameters such as Cₘₐₓ, Tₘₐₓ, AUC, half-life, and clearance would need to be determined through comprehensive PK studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for 1alpha, 25-Dihydroxy VD2-D6 are limited, as it is primarily used as an analytical standard and research compound. Vitamin D analogs are generally well-tolerated at physiological doses but can cause hypercalcemia at high doses. Standard toxicological assessments would include evaluation of calcium metabolism and organ function. As with all research chemicals, appropriate safety precautions should be taken when handling this compound.
|
| Additional Infomation |
1alpha, 25-Dihydroxy VD2-D6 is a research compound used as a deuterated standard for vitamin D analysis. No clinical trials or regulatory approvals have been reported for this compound as a therapeutic agent. It is available from various chemical suppliers for research purposes only. The compound is a deuterated form of vitamin D that has been extensively studied for its potential therapeutic and biological effects.
|
| Molecular Formula |
C28H44O3
|
|---|---|
| Molecular Weight |
428.64716
|
| Exact Mass |
434.367
|
| CAS # |
216244-04-1
|
| PubChem CID |
66577026
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.726
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
31
|
| Complexity |
758
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
O[C@H](C/1=C)C[C@H](O)CC1=C\C=C2[C@@](CC[C@@H]3[C@@H](/C=C/[C@H](C)C(C([2H])([2H])[2H])(C([2H])([2H])[2H])O)C)([H])[C@]3(C)CCC\2
|
| InChi Key |
ZGLHBRQAEXKACO-NHXRPVGSSA-N
|
| InChi Code |
InChI=1S/C28H44O3/c1-18(9-10-19(2)27(4,5)31)24-13-14-25-21(8-7-15-28(24,25)6)11-12-22-16-23(29)17-26(30)20(22)3/h9-12,18-19,23-26,29-31H,3,7-8,13-17H2,1-2,4-6H3/b10-9+,21-11+,22-12-/t18-,19+,23-,24-,25+,26+,28-/m1/s1/i4D3,5D3
|
| Chemical Name |
(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(E,2R,5S)-7,7,7-trideuterio-6-hydroxy-5-methyl-6-(trideuteriomethyl)hept-3-en-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3329 mL | 11.6645 mL | 23.3291 mL | |
| 5 mM | 0.4666 mL | 2.3329 mL | 4.6658 mL | |
| 10 mM | 0.2333 mL | 1.1665 mL | 2.3329 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
